<PAD>
<SOS>
<EOS>
<UNK>
6
adverse
reactions
the
following
serious
are
discussed
in
greater
detail
another
section
of
label
[
see
warnings
and
precautions
(
5
)
]
:
non
-
infectious
pneumonitis
5.1
.
infections
5.2
angioedema
with
concomitant
use
ace
inhibitors
5.3
oral
ulceration
5.4
renal
failure
5.5
impaired
wound
healing
5.6
because
clinical
trials
conducted
under
widely
varying
conditions
,
reaction
rates
observed
can
not
be
directly
compared
to
other
may
reflect
practice
excerpt
advanced
hr+
bc
pnet
rcc
most
common
incidence
30
%
include
stomatitis
rash
fatigue
diarrhea
edema
abdominal
pain
nausea
fever
asthenia
cough
headache
decreased
appetite
6.1
6.2
6.3
angiomyolipoma
tsc
is
6.4
sega
respiratory
tract
infection
6.5
report
suspected
contact
novartis
pharmaceuticals
corporation
at
1
888
669
6682
or
fda
800-fda-1088
www.fda.gov/medwatch
study
experience
hormone
receptor
positive
her2-negative
breast
cancer
efficacy
safety
afinitor
10
mg
day
plus
exemestane
25
n=485
versus
placebo
n=239
was
evaluated
a
randomized
controlled
trial
patients
metastatic
median
age
61
years
range
28
93
75
were
caucasian
results
based
on
follow
up
approximately
13
months
grade
3/4
2
hyperglycemia
dyspnea
laboratory
abnormalities
50
hypercholesterolemia
increased
aspartate
transaminase
ast
anemia
leukopenia
thrombocytopenia
lymphopenia
alanine
alt
hypertriglyceridemia
3
potassium
fatal
occurred
more
frequently
who
received
arm
0.4
treatment
emergent
events
resulting
permanent
discontinuation
24
for
groups
respectively
dose
adjustments
interruptions
reductions
frequent
among
than
63
14
table
compares
reported
an
receiving
daily
grading
according
ctcae
version
3.0
160
33.2
exposed
therapy
period
32
weeks
b
includes
mouth
aphthous
glossodynia
gingival
glossitis
lip
c
all
preferred
terms
within
'
infestations
system
organ
class
being
nasopharyngitis
urinary
upper
pneumonia
4
bronchitis
cystitis
sinusitis
also
including
candidiasis
sepsis
hepatitis
d
interstitial
lung
disease
infiltration
pulmonary
fibrosis
e
exposure
+
n=482
n=238
grades
any
100
41
9
90
22
gastrointestinal
disorders
67
8
0
11
0.8
33
0.2
18
29
vomiting
17
12
constipation
dry
7
general
administration
site
36
27
peripheral
19
pyrexia
15
investigations
weight
metabolism
nutrition
musculoskeletal
connective
tissue
arthralgia
20
back
extremity
nervous
dysgeusia
21
psychiatric
insomnia
thoracic
mediastinal
0.6
epistaxis
skin
subcutaneous
39
pruritus
alopecia
vascular
hot
flush
duration
23.9
13.4
key
presented
reflects
corresponding
drug
reports
neutropenia
collectively
as
pancytopenia
which
lower
frequency
parameter
hematology
hemoglobin
68
40
wbc
58
platelets
54
lymphocytes
37
neutrophils
31
chemistry
glucose
69
44
cholesterol
70
38
45
51
triglycerides
26
albumin
16
creatinine
pancreatic
neuroendocrine
tumors
n=204
n=203
87
79
55
male
could
cross
over
open
upon
progression
alkaline
phosphatase
bicarbonate
hypophosphatemia
deaths
during
double
blind
where
event
primary
cause
seven
one
patient
causes
death
included
case
each
acute
distress
cardiac
arrest
unknown
hepatic
there
due
embolism
after
three
additional
hypoglycemia
insulinoma
myocardial
infarction
congestive
heart
sudden
delay
reduction
necessary
everolimus
six
thrombotic
five
embolus
well
thrombosis
two
swelling
tongue
mucosal
inflammation
enteritis
enterocolitis
colitis
defecation
urgency
steatorrhea
restrictive
49
98
0.5
malaise
rhinitis
uri
diabetes
mellitus
muscle
spasms
migraine
dizziness
productive
exertional
oropharyngeal
59
nail
generalized
xeroderma
hypertension
wks
female
aged
irregular
menstruation
46
treated
females
none
group
86
43
74
66
fasting
53
56
48
35
phosphate
calcium
23
sodium
bilirubin
cell
carcinoma
data
described
below
n=274
n=137
prior
sunitinib
and/or
sorafenib
85
88
78
blinded
141
days
451
60
295
those
dehydration
0.7
but
irrespective
causality
leading
reasons
medical
interventions
required
meddra
order
decreasing
least
higher
rate
aspergillosis
alveolar
hemorrhage
toxicity
alveolitis
dverse
r
eaction
97
52
isorders
i
nfestations
dministration
s
ite
onditions
t
horacic
m
ediastinal
ubcutaneous
issue
n
utrition
anorexia
ystem
onnective
medi
uration
reatment
notable
occurring
hemorrhoids
dysphagia
chest
chills
pleural
effusion
pharyngolaryngeal
rhinorrhea
hand
foot
syndrome
palmar
plantar
erythrodysesthesia
disorder
erythema
onychoclasis
lesion
acneiform
dermatitis
exacerbation
pre
existing
new
onset
paresthesia
eye
eyelid
conjunctivitis
deep
vein
tachycardia
jaw
hematologic
p
arameter
92
hemistry
77
73
34
57
tuberous
sclerosis
complex
2:1
118
feature
n=113
sporadic
lymphangioleiomyomatosis
n=5
89
115
amenorrhea
abnormality
3.8
hypersensitivity
bronchospasm
convulsion
adjustment
separately
n=79
n=39
acne
involving
reproductive
menorrhagia
menstrual
irregularities
vaginal
less
-treated
otitis
media
depression
abnormal
taste
blood
luteinizing
lh
levels
follicle
stimulating
fsh
ovarian
cyst
leucopenia
elevated
subependymal
giant
astrocytoma
117
9.5
47
gastroenteritis
aggression
agitation
partial
thromboplastin
time
no
viral
anxiety
panic
attack
behavior
obsessive
compulsive
macular
maculo
papular
allergic
urticaria
n=78
62
pharyngitis
streptococcal
behavioral
disturbance
this
same
dysmenorrhea
metrorrhagia
unspecified
irregularity
72
81
longer
term
34.2
4.7
47.1
from
28-patient
resulted
cellulitis
6.6
postmarketing
have
been
identified
post
approval
these
voluntarily
population
uncertain
size
it
always
possible
reliably
estimate
establish
causal
relationship
pancreatitis
cholecystitis
cholelithiasis
arterial
reflex
sympathetic
dystrophy
monitor
symptoms
radiological
changes
;
cases
manage
by
until
resolve
consider
corticosteroids
risk
some
signs
treat
promptly
taking
inhibitor
ulcers
mucositis
management
mouthwashes
topical
treatments
outcome
related
complications
exercise
caution
peri
surgical
test
alterations
elevations
serum
protein
lipids
occur
decreases
function
parameters
periodically
thereafter
5.8
vaccinations
avoid
live
vaccines
close
5.11
embryo
fetal
harm
when
administered
pregnant
woman
apprise
women
potential
fetus
5.12
8.1
effect
rapamycin
derivatives
terminology
criteria
ctc
4.0
outcomes
diagnosis
presenting
specific
such
hypoxia
whom
neoplastic
excluded
means
appropriate
opportunistic
pneumocystis
jiroveci
pjp
should
considered
differential
advise
worsening
develop
suggestive
few
continue
without
alteration
imaging
appears
overestimate
if
moderate
interrupting
improve
indicated
reintroduced
previously
dosage
2.2
interrupt
resolution
equal
re
introduced
depending
individual
circumstances
recurs
discontinue
require
prophylaxis
development
has
even
reduced
immunosuppressive
properties
predispose
bacterial
fungal
protozoal
pathogens
localized
systemic
mycobacterial
invasive
reactivation
virus
severe
e.g.
physicians
aware
complete
starting
while
vigilant
made
institute
interruption
antifungal
associated
agents
angiotensin
converting
enzyme
airways
impairment
pooled
analysis
oncology
6.8
1.3
control
ranging
44%-78
across
4%-9
recommended
alcohol-
hydrogen
peroxide-
iodine-
thyme-
containing
avoided
they
exacerbate
condition
used
unless
diagnosed
interactions
7.1
tests
monitoring
delays
increases
occurrence
like
dehiscence
incisional
hernia
lymphocele
seroma
intervention
5.7
geriatric
last
65
careful
populations
8.5
proteinuria
measurement
urea
nitrogen
bun
start
monitored
particularly
factors
that
further
impair
hyperlipidemia
lipid
profile
co
drugs
induce
optimal
achieved
before
count
5.9
significant
strong
cyp3a4
pgp
2.5
increase
inducer
7.2
5.10
pharmacology
12.3
child
pugh
desired
benefit
outweighs
mild
adjust
tablets
disperz
therapeutic
reduce
subsequent
doses
2.4
individuals
intranasal
influenza
measles
mumps
rubella
polio
bcg
yellow
varicella
ty21a
typhoid
pediatric
do
immediate
childhood
series
american
council
immunization
practices
acip
guidelines
accelerated
vaccination
schedule
mechanism
action
caused
toxicities
animals
maternal
exposures
human
pregnancy
becomes
apprised
hazard
becoming
highly
effective
contraception
using
ending
8.6
studies
seizures
anaphylaxis
ampyra
balance
multiple
relapse
dyspepsia
acorda
therapeutics
800
367
5109
15/400
twice
experienced
5/238
led
confusional
state
0.3
lists
ms
placebo(n=238
ampyra10
daily(n=400
total
1,952
subjects
917
741
501
year
352
consistent
dependent
follows
0.41
per
person
95
confidence
interval
0.13
0.96
dalfampridine
1.7
0.21
6.28
increasing
restart
seizure
occurs
taken
forms
4-aminopyridine
4-ap
fampridine
since
active
ingredient
extension
1.7/100py
times
0.4/100py
marketing
majority
history
generally
evidence
epileptiform
activity
eeg
substantially
discontinued
restarted
contraindicated
contraindications
eliminated
through
kidneys
primarily
unchanged
12.4
crcl
50ml
min
would
strength
smaller
available
80
ml
plasma
approach
seen
concurrent
product
initiating
compromise
throat
informed
instructed
seek
care
17.3
utis
clinically
followed
pressure
injection
eli
lilly
company
800-lillyrx
545
5979
555
amyvid
predominantly
severity
subject
shown
n=555
haemorrhage
irritation
feeling
cold
percent
1.8
claustrophobia
neck
frequencies
infusion
pruritis
flushing
image
interpretation
errors
especially
false
negatives
radiation
similar
radiopharmaceuticals
contributes
's
long
cumulative
ensure
safe
handling
protect
health
workers
unintentional
2.1
misinterpretation
estimation
brain
neuritic
plaque
density
performed
independently
information
images
lead
extensive
atrophy
limits
ability
distinguish
gray
white
matter
scan
motion
artifacts
distort
indicative
amyloid
content
only
acquisition
negative
result
does
preclude
future
overall
suicidal
ideation
dermatologic
eosinophilia
dress)/multiorgan
anaphylactic
hyponatremia
neurological
induced
liver
injury
thyroid
aptiom
somnolence
diplopia
vertigo
ataxia
blurred
vision
tremor
sunovion
877
737
7226
monotherapy
14.1
365
225
134
between
old
84
uncontrolled
adjunctive
1195
586
462
1021
historical
epilepsy
receive
1200
1600
once
commonly
attributed
did
established
incidences
aed
withdrawal
phase
titration
descending
dysarthria
gives
began
initial
400
week
then
initiated
adults
n=426
n=415
n=410
ear
labyrinth
visual
211
962
1151
gastritis
53311<1
1064222
1610222<1
gait
42<11
4222
7321
poisoning
procedural
fall
memory
nystagmus
9892<110<1<1
201113432111
281815634222
slightly
hematocrit
ldl
creatine
phosphokinase
gender
race
differences
noted
although
thoughts
dress
experiencing
coordination
cognitive
dysfunction
driving
operating
machinery
withdraw
gradually
minimize
status
epilepticus
2.6
jaundice
antiepileptic
aeds
indication
emergence
unusual
mood
analyses
199
mono-
different
showed
had
adjusted
relative
ci
1.2
2.7
thinking
estimated
27,863
0.43
0.24
16,029
representing
every
530
four
suicides
number
too
small
allow
conclusion
about
suicide
early
persisted
assessed
extend
beyond
analyzed
finding
mechanisms
indications
suggests
applies
vary
shows
absolute
behaviors
1000
1.0
3.4
3.5
1.5
2.9
1.9
0.9
4.3
anyone
considering
prescribing
must
untreated
illness
many
illnesses
prescribed
themselves
morbidity
mortality
emerge
prescriber
needs
whether
given
their
caregivers
families
advised
need
alert
self
concern
immediately
healthcare
providers
stevens
johnson
sjs
association
sometimes
toxic
epidermal
necrolysis
ten
oxcarbazepine
carbamazepine
chemically
reporting
exceeds
background
estimates
factor
3-
10-fold
develops
clearly
either
known
multiorgan
life
threatening
typically
exclusively
presents
lymphadenopathy
involvement
nephritis
hematological
myocarditis
myositis
resembling
often
present
variable
its
expression
systems
here
involved
important
note
manifestations
though
evident
resumed
alternative
etiology
rare
laryngeal
type
125
meq
l
4/415
6/410
value
assigned
percentage
values
l.
effects
appeared
first
low
112
instability
hospitalization
hypochloremia
chloride
maintenance
medications
decrease
lethargy
confusion
irritability
weakness
obtundation
vs.
older
younger
therefore
modifications
both
concomitantly
2.3
hypersomnia
sedation
attention
amnesia
aphasia
speech
slowness
thought
disorientation
psychomotor
retardation
hazardous
activities
prescribers
against
engaging
requiring
mental
alertness
motor
vehicles
dangerous
withdrawn
transaminases
limit
normal
baseline
evaluations
combination
obstruction
recognized
predictor
t3
t4
free
suggesting
hypothyroidism
ong
acting
beta
-adrenergic
agonists
rcapta
neohaler
asthma
arcapta
oxed
warning
w
arning
chronic
obstructive
database
2516
mcg
confirmatory
449
144
583
425
copd
150
300
600
mean
bronchodilator
forced
expiratory
volume
second
fev1
predicted
64
proportion
angina
pectoris
atrial
fibrillation
displays
month
listed
13.0
sorted
indacaterol
n=449
n=
445
4.5
cardiovascular
1.6
dosed
spasm
ough
ost
inhalation
clinic
visits
average
usually
seconds
lasted
exacerbations
deteriorations
loss
6-month
805
adult
persistent
n=268
salmeterol
n=269
inhaled
addition
511
intubations
worldwide
paradoxical
palpitations
boxed
agonist
laba
large
us
added
usual
ontraindications
arnings
full
beta2-adrenergic
initiate
acutely
deteriorating
relief
short
beta2-agonists
needed
exceed
excessive
conjunction
convulsive
thyrotoxicosis
sensitivity
sympathomimetic
determine
28-week
comparing
13/13,176
3/13,179
rr
4.37
1.25
15.34
adequate
sizes
precisely
quantify
deterioration
episodes
studied
setting
inappropriate
i.e.
rescue
extra
purpose
beta2-agonist
beginning
regular
basis
them
symptomatic
provider
prescribe
beta2-
instruct
how
signal
prompt
deteriorate
hours
chronically
several
controls
bronchoconstriction
markers
evaluation
regimen
undertaken
situation
overdose
fatalities
particular
difficulties
breathing
swallowing
lips
face
instituted
produce
measured
pulse
systolic
diastolic
ecg
flattening
wave
prolongation
qtc
st
segment
significance
findings
amines
coronary
insufficiency
arrhythmias
coexisting
unusually
responsive
albuterol
intravenously
aggravate
ketoacidosis
hypokalemia
possibly
intracellular
shunting
12.2
transient
supplementation
high
infrequent
investigated
whose
instillation
bausch
&
lomb
incorporated
323
0000
rarely
bepreve
casual
itching
body
contamination
touch
dropper
tip
surface
keep
bottle
tightly
closed
lens
remove
lenses
solution
contaminating
eyelids
surrounding
areas
wear
red
instilled
wearing
preservative
benzalkonium
absorbed
soft
reinserted
minutes
ophthalmic
besivance
1,000
ocular
conjunctival
redness
growth
resistant
organisms
prolonged
avoidance
course
into
injected
subconjunctivally
nor
anterior
chamber
anti
infectives
besifloxacin
suspension
overgrowth
susceptible
fungi
super
whenever
judgment
dictates
examined
aid
magnification
slit
lamp
biomicroscopy
fluorescein
staining
sections
cytokine
release
tumor
lysis
febrile
drive
machines
enzymes
leukoencephalopathy
preparation
}
amgen
inc.
77-amgen
772
6436
blincyto
212
relapsed
refractory
asian
black
african
device
encephalopathy
staphylococcal
bacteremia
reason
remission
summarized
gradegrading
nci
4.0(%
higher(%
lymphatic
251816119
23131588
diarrheadiarrhea
neutropenic
2520201513
1120
6225171511
1101
immune
pathogen
4419151397
25127486
aminotransferase
121111
640
hypomagnesemia
231211106
60735
bone
14121110
2132
tremortremor
resting
362014
dyspneadyspnea
bronchial
hyperactivity
wheezing
1915
05
rashrash
erythematous
vesicular
hypotension
meet
threshold
inclusion
leukocytosis
storm
immunoglobulins
gamma
glutamyl
transferase
hypoalbuminemia
capillary
leak
immunogenicity
proteins
electrochemiluminescence
detection
technology
ecl
linked
immunosorbent
assay
elisa
screening
immunoassay
binding
blinatumomab
antibodies
sera
tested
vitro
biological
detect
neutralizing
antibody
formation
affect
pharmacokinetics
discuss
testing
specificity
additionally
positivity
influenced
methodology
sample
timing
collection
underlying
comparison
products
misleading
crs
appropriately
refrain
occupations
heavy
potentially
strictly
instructions
admixing
indistinguishable
infrequently
disseminated
intravascular
coagulation
dic
cls
hemophagocytic
lymphohistiocytosis
macrophage
activation
hlh
mas
closely
temporary
initiation
convulsions
disturbances
consciousness
resolved
catheter
administer
prophylactic
antibiotics
employ
surveillance
tls
measures
pretreatment
nontoxic
cytoreduction
hydration
prevention
limited
neutrophil
neurologic
outside
ggt
rise
rises
cranial
magnetic
resonance
mri
showing
irradiation
antileukemic
chemotherapy
methotrexate
intrathecal
cytarabine
medication
underdose
labeling
myelosuppression
fluid
retention
pfizer
438
1985
shock
hepatotoxicity
1/2
n=546
82
imatinib
-intolerant
ph+
cp
ap
blast
bp
cml
single
enrolled
myelogenous
leukemia
resistance
intolerance
bosulif
546
287
intensity
484
119
tki
475
140
76
483
500
cohorts
identifies
cmln=406
cmln=140
grades(%
3/4(%
42
qtcf
milliseconds
qt
protocol
relevant
advp
n=406
n=140
platelet
/l
102
182
126
g
biochemistry
sgpt
5.0*uln
sgot
lipase
2*uln
8)
phosphorus
mmol
3.0*uln
represent
870
agent
ranked
relevance
seriousness
category
pericardial
0.1
pericarditis
tinnitus
gastric
administrative
discomfort
hepatobiliary
cytolytic
bronchopneumonia
lobar
atypical
electrocardiogram
hyperkalemia
myalgia
multiforme
exfoliative
eruption
withhold
counts
monthly
standard
embryofetal
standards
antidiarrheals
antiemetics
replacement
221
perform
weekly
defined
3*uln
letrozole
recovered
fully
represented
out
1209
elevation
twenty
manifest
specifically
effusions
decline
glomerular
filtration
egfr
shift
lowest
global
0.03
n=818)among
818
missing
kidney
normaln
mildn
moderaten
severen
failuren
notes
modification
diet
method
mdrd).kdigo
classification
min/1.73
274
174
170
177
816
349
236
120
preexisting
bosutinib
rabbits
vilanterol
ingredients
breo
ellipta
currently
inadequate
mitigates
suggest
adolescent
local
corticosteroid
candida
albicans
immunosuppression
hypercorticism
adrenal
suppression
mineral
5.13
dysphonia
glaxosmithkline
825
5249
program
7,700
12-month
shorter
2,034
100/25
1,087
fluticasone
furoate
6-
1,224
1,030
2,254
smoking
pack
current
smokers
postbronchodilator
fev1was
vital
capacity
fvc
ratio
reversibility
-41
152
200/25
mcg/25
200
=3
410
408
412
oropharyngitis
1,633
1,622
3,255
91
indicating
very
severely
airflow
806
parallel
9,969
2,369
956
approved
8.4
12-week
24-week
609
201
205
203
1,039
346
347
propionate
tables
202
adolescents
extrasystoles
supraventricular
ventricular
24-
76-week
1,009
1,010
participating
emergency
department
visit
entry
hospitalizations
151
130
postapproval
chosen
connection
nervousness
ics
treating
adequately
warrants
maintained
assess
intervals
step
down
maintain
low-
medium
ics.(1.2
medicine
pharynx
rinse
his
her
water
help
tuberculosis
parasitic
herpes
simplex
chickenpox
transferring
taper
slowly
dosages
adrenergic
stimulation
initially
glaucoma
cataracts
warranted
5.14
5.15
5.16
rapidly
reevaluation
marker
requires
reassessment
giving
special
consideration
replacing
adding
medicines
formoterol
fumarate
arformoterol
tartrate
continues
interrupted
pneumonias
remain
features
overlap
replicate
previous
820
811
persons
suppress
healthy
example
children
diseases
properly
immunized
route
developing
contribution
zoster
globulin
vzig
intramuscular
immunoglobulin
ig
respective
package
inserts
antiviral
quiescent
transferred
systemically
transfer
recovery
hypothalamic
pituitary
hpa
prednisone
equivalent
almost
completely
exhibit
trauma
surgery
electrolyte
supplies
physiological
amounts
glucocorticoid
provide
mineralocorticoid
coping
emergencies
periods
stress
resume
instruction
carry
card
supplementary
weaned
accomplished
reducing
fev1or
peak
flow
carefully
lassitude
unmask
suppressed
eczema
arthritis
eosinophilic
joint
muscular
despite
improvement
circulation
axis
however
exceeding
coadministration
cytochrome
p450
3a4
possibility
absorption
sensitive
observing
postoperatively
response
crisis
appear
accepted
procedures
exercised
ketoconazole
ritonavir
clarithromycin
conivaptan
indinavir
itraconazole
lopinavir
nefazodone
nelfinavir
saquinavir
telithromycin
troleandomycin
voriconazole
dosing
milk
allergy
powder
lactose
electrocardiographic
12-
producing
bmd
regard
consequences
fracture
major
immobilization
family
osteoporosis
postmenopausal
tobacco
poor
mass
anticonvulsants
assessment
still
medically
prevent
strongly
intraocular
change
beta2-adrenoceptor
evaluating
5.17
orally
velocity
exclusive
uncommon
choline
division
nuclear
radiology
mayo
507
284
2511
psa
ng
performance
resuscitation
equipment
personnel
readily
worker
pet
ct
rule
presence
recurrent
prostate
confirm
uptake
types
correlation
histopathological
recurrence
essential
proper
numbers
prostatic
hyperplasia
colchicine
androgen
deprivation
releasing
analogs
interfere
published
f
methylcholine
impact
injectable
risks
ensured
ucb
866
822
0068
malignancies
predict
broader
premarketing
combined
crohn
cimzia
intestinal
rheumatoid
620
614
cd2
1,564
level
1,350
94
ages
laryngitis
bladder
bacteriuria
above
thrombophilia
hypertensive
ischemia
stroke
ischemic
optic
neuritis
retinal
uveitis
bleeding
totalis
bipolar
attempt
nephrotic
nodosum
thrombophlebitis
vasculitis
2,367
ra
2,030
1,663
282
1,774
suffering
summarizes
saline
formulation
reaction(preferred
placebo+
mtx(%)n
324
eow
steroidal
inflammatory
psoriatic
409
ankylosing
spondylitis
325
axial
spondyloarthritis
as-1
consisted
pyelonephritis
0.91
0.72
0.06
0.02
0.04
continued
completed
ongoing
5,118
0.61
countries
endemic
tb
miliary
peritoneal
345
tnf
blockers
autoantibodies
ana
titers
developed
lupus
autoimmune
points
certolizumab
pegol
cd1
continuously
apparent
immunosuppressants
1,242
detectable
occasion
105
1,509
third
mtx
immunosuppressant
ii
iii
iv
loading
lowered
concentration
acr20
meaningful
compatible
postural
sickness
vasovagal
syncope
psoriasis
sub
pustular
palmoplantar
sarcoidosis
malignancy
latent
extrapulmonary
histoplasmosis
coccidioidomycosis
blastomycosis
pneumocystosis
rather
antigen
empiric
legionella
listeria
benefits
lymphoma
member
stop
reside
travel
regions
mycoses
hbv
carriers
begin
demyelinating
cytopenias
stopping
various
sites
legionellosis
listeriosis
morbid
resided
traveled
blocking
induration
mm
tuberculin
assessing
vaccinated
bacille
calmette
guerin
past
confirmed
having
consultation
physician
expertise
decision
recently
prevalence
falsely
undergo
diagnostic
workup
immunocompromised
antimicrobial
feasible
take
account
portions
labeled
excluding
melanoma
4,650
1,319
precludes
draw
firm
conclusions
young
half
lymphomas
hodgkin
variety
derived
sources
registries
spontaneous
investigational
uses
2,657
2-fold
expected
therapies
absence
blocker
role
hepatosplenic
hstcl
aggressive
males
ulcerative
azathioprine
6-mercaptopurine
6-mp
periodic
examinations
chf
formally
towards
instances
contribute
throughout
termination
supportive
resuming
resumption
radiographic
central
guillain
barre
recent
neuropathy
aplastic
cytopenia
remains
unclear
dyscrasias
bruising
pallor
modifying
antirheumatic
dmards
anakinra
interleukin-1
antagonist
etanercept
alone
abatacept
rituximab
nature
autoimmunity
immunizations
except
attenuated
secondary
transmission
difference
detected
vaccine
pneumococcal
polysaccharide
concurrently
proportions
protective
humoral
mediates
modulates
cellular
responses
exists
host
defenses
understood
elsewhere
977-mdco
6326
cleviprex
99
1307
clevidipine
1406
1099
perioperative
hour
infused
n=1199
continuous
durations
brief
"
escape-1
escape-2
exceeded
clvn=53(%
pbon=51(%
clvn=61(%
pbon=49(%
--
called
eclipse
define
n=752
comparator
nitroglycerin
ntg
n=278
nitroprusside
snp
n=283
nicardipine
nic
n=193
maximum
operative
procedure
relatively
plausibly
thus
differentiate
end
comparators
3.2
n=126
4.8
arrestnervous
syncoperespiratory
ileus
oxygen
saturation
aseptic
technique
discard
unused
portion
stopper
puncture
rapid
upward
dihydropyridine
channel
inotropic
protection
abrupt
infusions
transitioned
antihypertensive
rebound
stopped
intake
contains
2.0
kcal
restrictions
quantity
compensate
amount
part
inotropy
gradual
pheochromocytoma
guide
otherwise
6-dose
coartem
1,979
647
1,332
366
1,613
malaria
71
thailand
africa
show
collected
worsened
comparative
antimalarial
1.1
1/647
21/1,332
n=647
360
253
260
243
159
147
111
219
206
169
113
sleep
hepatomegaly
splenomegaly
n=1,332
381
302
242
plasmodium
falciparum
224
175
168
124
<3
regardless
peptic
ulcer
abscess
acrodermatitis
helminthic
hookworm
impetigo
lymphocyte
morphology
clonus
fine
hyperreflexia
hypoesthesia
swings
hematuria
pharyngo
bullous
prolong
5.1,12.6
halofantrine
additive
5.1,5.2,12.3
antimalarials
option
prolonging
quinine
quinidine
cautiously
5.1,5.2,7.7,12.3
substrates
inducers
antiretroviral
5.3,7.2,7.3
congenital
bradycardia
ia
procainamide
disopyramide
amiodarone
sotalol
antiarrhythmic
antipsychotics
pimozide
ziprasidone
antidepressants
certain
macrolide
fluoroquinolone
imidazole
triazole
12.6
metabolized
cyp2d6
flecainide
imipramine
amitriptyline
clomipramine
7.6
elimination
lumefantrine
7.7
mefloquine
bile
production
food
consumption
encouraged
7.4
coadministered
concentrations
substrate
grapefruit
juice
artemether
potentiate
mixed
hiv
protease
nucleoside
reverse
transcriptase
7.3
effectiveness
hormonal
contraceptives
transdermal
patch
birth
7.5
significantly
recrudescence
enhances
averse
recrudescent
p.
vivax
erythrocytic
stage
relapsing
achieve
radical
cure
eradicate
hypnozoites
dormant
perforations
fistula
thromboembolic
osteonecrosis
reversible
posterior
ppes
hair
color
hypocalcemia
hyperbilirubinemia
exelixis
855
3935
cometriq
330
progressive
medullary
214
109
intolerable
doubleblind
204
alp
septicemia
fistulas
tracheal
tsh
ninety
thyroidectomy
selected
xl184
301
grades)national
cometriq(n=214
placebo(n=109
allgrades
grades3
sensory
changes/
depigmentation
graying
hyperkeratosis
grade3
chemistries
nearly
96
doubling
overt
modified
national
committee
jnc
staging
malignant
jncstage
cometriqn=211(%
placebon=107(%
mmhg
cometriqtm
perforation
hemoptysis
andhemorrhage
cerebral
regularly
urine
rpls
gi
esophageal
hemorrhagic
venous
thromboembolism
complication
scheduled
onj
osteomyelitis
osteitis
erosion
tooth
periodontal
toothache
slow
dental
examination
regarding
good
hygiene
subcortical
vasogenic
characteristic
altered
cabozantinib
embryolethal
rats
skeletal
variations
visceral
malformations
cubist
877-cubist-6
4786
dificid
564
cdad
86.7
thirty
withdrew
ar
varied
considerably
fidaxomicin
vancomycin
n=564
n=583
distension
tenderness
flatulence
megacolon
metabolic
acidosis
arise
voluntary
reliability
estimating
establishing
bacteria
proven
c.
difficile
minimal
macrolides
unlikely
gbcas
nsf
clear
dotarem
coldness
burning
sensation
guerbet
llc
729
6679
2813
2672
men
ethnicity
recorded
ethnic
distribution
others
3.9
n=2813
extravasation
warmth
arrhythmia
/anaphylactoid
cyanosis
pharyngeal
laryngospasm
hyperemia
lacrimation
hyperhidrosis
coma
presyncope
parosmia
contracture
salivary
hypersecretion
confounded
receipt
situations
ruled
unconfounded
superficial
phlebitis
nephrogenic
gadolinium
contrast
contrasted
modalities
debilitating
affecting
internal
organs
highest
gfr
m2
oracute
screen
sufficient
repeat
anaphylactoid
cutaneous
uncommonly
cardiorespiratory
support
gbca
little
consist
repeated
degree
record
hemodialysis
enhance
usefulness
circulatory
collapse
died
trained
observe
dialysis
obtaining
assessments
patency
tissues
nonclinical
toxicology
13.2
neoplasms
gallbladder
prospective
conjugated
estrogens
bazedoxifene
enrolling
6,210
duavee
1,069
vitamin
iu
0.0
10.0
n=1224)n
n=1069)n
110
conclude
estrogen
endometrial
probable
dementia
uterus
unopposed
precursor
directed
random
sampling
undiagnosed
recurring
genital
initiative
whi
substudy
dvt
0.625
mg)-alone
whims
ancillary
comparable
assumed
shortest
goals
informationduavee
dew
ah
vee)(conjugated
bazedoxifene)tablets
read
you
get
refill
place
talking
your
what
know
?
chance
getting
womb
right
away
menopause
sign
check
find
attacks
strokes
chances
clots
talk
prescription
mixture
flushesestrogens
hormones
ovaries
normally
making
drop
removed
operation
natural
takes
"when
dropping
uncomfortable
feelings
intense
heat
sweating
flashes
flushes
will
thin
weak
bones)if
might
better
people
problems
list
leaflet
cancers
think
breastfeeding
plan
breastfeed
passes
decide
tell
my
endometriosis
going
bed
rest
let
counter
vitamins
herbal
supplements
progestins
ask
works
work
pharmacist
comes
blister
date
foil
pouch
space
provided
exactly
tells
tablet
swallowed
whole
ready
pill
boxes
organizers
miss
soon
remember
next
skip
missed
sure
call
supplement
much
nauseavomitingbreast
tendernessdizzinessabdominal
painfeeling
tiredvaginal
side
grouped
happen
lining
ovary
fats
migraines
genetic
problem
porphyria
lumps
headaches
pains
legs
shortness
breath
upset
stomach
bother
go
doctor
advice
pelvic
exam
mammogram
x
ray
something
else
members
ever
exams
fat
overweight
ways
store
room
temperature
degrees
moisture
opening
blisters
come
reach
purposes
give
written
professionals
www.duavee.com
estrone
sulfate
equilin
components
conjugates
17alpha
dihydroequilin
estradiol
17beta
inactive
tribasic
hydroxypropyl
cellulose
microcrystalline
powdered
hypromellose
monohydrate
magnesium
stearate
polyethylene
glycol
sucrose
ascorbic
acid
palmitic
ester
hydroxyethylcellulose
titanium
dioxide
iron
oxide
povidone
polydextrose
maltitol
poloxamer
188
propylene
isopropyl
alcohol
u.s.
updated
please
www.pfizer.com
lab-0583
october
2013
antagonists
cholestatic
component
individually
vte
obesity
personal
erythematosus
managed
statistically
ce
10,000
demonstrated
14.5
subgroup
chd
nonfatal
silent
mg]-alone
pe
reached
statistical
independent
ambulatory
move
users
greatest
15-
24-fold
persist
reduces
providing
0.80
mammograms
yearly
mammography
epidemiological
epidemiologic
2,947
hysterectomized
1.49
0.83
2.66
14.6
2-
4-fold
pending
proptosis
reveals
papilledema
lesions
permanently
substantial
idiosyncratic
poorly
4.3-fold
8.7
leads
tbg
maintaining
acceptable
warrant
observation
hypoparathyroidism
hereditary
exogenous
hemangiomas
premenopausal
useful
vasomotor
prothrombin
aggregation
vii
viii
coagulant
ix
xii
thromboglobulin
antifactor
xa
antithrombin
fibrinogen
plasminogen
circulating
bound
iodine
pbi
column
radioimmunoassay
resin
reflecting
unaltered
cbg
sex
shbg
steroids
testosterone
angiotensinogen
renin
alpha-1-antitrypsin
ceruloplasmin
lipoprotein
hdl
hdl2
subfraction
triglyceride
tolerance
nerve
damage
acuity
field
defects
subcapsular
cataract
globe
thinning
cornea
sclera
durezol
corneal
ciliary
photophobia
capsule
opacification
cells
flare
blepharitis
punctate
keratitis
iritis
application
pigmentation
striae
episcleritis
crusting
foreign
consequence
endogenous
participated
106
iop
limbal
iridocyclitis
increase-
fields
item
{
cataracts-
delayed
healing-
bleb
causing
renewal
infections-
purulent
mask
fail
employment
great
prone
coincidentally
steroid
fungus
invasion
alcon
laboratories
757
9195
culture
distant
spread
toxin
seeboxed
lack
interchangeability
botulinum
seewarnings
facial
anatomy
glabellar
lines
neuromuscular
intradermal
cervical
dystonia
ptosis
limb
spasticity
depression.(6.1
ipsen
biopharmaceuticals
397
7671
dysport
357
optional
optimization
250
units
cycles
allowed
entirely
58.4
consisting
accommodation
became
noticeable
cycle
seeclinical
units(n=173
placebo(n=182
relationships
fixed
divided
muscles
sternocleidomastoid
splenius
capitis
83
paresis
difficulty
mainly
exhibited
0.23
mol
placebo-
difficult
measurements
averaging
beats
minute
reactions(>=2
398
appearance
n=398
placebon=496
twelve
1425/2491
numbness
tingling
stinging
tightness
injections
seedosage
units(n=197)%
units(n=194)%
n=279)%
hypoaesthesia
contusion
investigation
haematoma
etc
hypertonia
heaviness
amyotrophy
granulation
1554
nine
230
separate
281
3.6
indicate
dysport(r
area
incontinence
probably
unapproved
potency
interchangeable
preparations
converted
creutzfeldt
jakob
cjd
utilized
seedescription
toxins
pre-
weakening
feeding
tube
aspiration
already
compromised
weaken
serve
accessory
ventilation
critical
become
5.2),adverse
6.1),clinical
administering
target
muscle(s
marked
asymmetry
site(s
dermatochalasis
dermal
scarring
thick
sebaceous
inability
lessen
physically
spreading
apart
14.2
neuropathic
amyotrophic
lateral
junction
myasthenia
gravis
lambert
eaton
typical
seeadverse
derivative
donor
manufacturing
processes
carries
extremely
remote
theoretical
intradermally
entereg
undergoing
surgeries
bowel
resection
merck
sharp
dohme
corp.
subsidiary
co.
4231
identifying
approximating
1,793
hospital
discharge
postoperative
alvimopan
entereg(r
restricted
mitigation
strategy
rems
access
education
e.a.s.e.(r
infarctions
opioids
correction
anastomosis
538
267
imbalance
1,142
1,120
restricts
hospitals
e.a.s.e.
requirements
hospitalized
met
enroll
authorized
representative
acknowledge
staff
dispense
educational
materials
inpatient
dispensed
discharged
www.enteregrems.com
278
0340
opioid
tolerant
mu
acts
peripherally
consecutive
anastomoses
reactionsare
bayer
84-bayer
842
2937
eovist
1,989
1,581
hispanic
1581
akathisia
bundle
branch
block
palpitation
maculopapular
returned
anaphylacticshock
sneezing
restlessness
ochronic
min/1.73m2
oroacute
enhanced
administrated
dual
excretory
pathways
myocyte
necrosis
interference
determination
complexometric
methods
ferrocene
complexation
caloxetate
trisodium
excipients
visualization
markedly
ferritin
abnormally
dl
later
paired
set
erwinaze
jazz
520
5568
multi
center
master
emtp
expanded
intravenous
pharmacokinetic
pk
erwinaze.study
nci)-sponsored
cooperative
protocols
unable
pegaspargase
25,000
international
intramuscularly
monday
wednesday
friday
remaining
original
latino
courses
ranged
planned
fourteen
completion
choice
frontline
.study
lymphoblastic
lbl
native
e.
coli
asparaginase
unit
/dose
indian
alaska
1368
-derived
940
schedules
specifications
20,000
n=852
n=29
n=59
seventy
eight
693
893
able
prospectively
systematically
interest
coagulopathy
infarct
cns
requested
ada
erwinaze.in
13.3
erwinaze.immunogenicity
5.1)severe
irreversible
insulin
evaluate
manifested
amylase
uln
contraindication
hold
subside
return
sagittal
sinus
erwinia
2-week
thrombin
endophthalmitis
detachments
eylea
vitreous
floaters
detachment
regeneron
395
3248
2711
constituted
2110
intravitreal
neovascular
wet
degeneration
amd
1824
1223
2-mg
masked
view1
view2
eylea(n=1824
ranibizumab)(n=595
epithelium
defect
pigment
eyes
tear
occlusion
rvo
218
crvo
copernicus
galileo
brvo
vibrant
14.2),(14.3
eylea(n=218
control(n=142
eylea(n=91
control(n=92
diabetic
dme
578
vivid
vista
14.4
eylea(n=578
control(n=287
samples
immunoassays
assays
immunoreactivity
vegf
2.7)andpatient
counseling
sustained
endothelial
perfusion
head
ates
3.3
2.8
4.2
chromaturia
apopharma
telephone
949
0995
email
medicalsafety@apopharma.com
agranulocytosis
zinc
ferriprox
represents
642
10.4
9.8
arthropathy
1.4
reddish
brown
discoloration
excretion
thrombocytosis
familial
hypospadias
rectal
parotid
gland
enlargement
nfections
cryptococcal
enteroviral
encephalitis
furuncle
chondropathy
trismus
cerebellar
intracranial
skills
pyramidal
bruxism
glycosuria
hemoglobinuria
periorbital
photosensitivity
henoch
schonlein
purpura
precede
measure
anc
/neutropenia
foreshadow
implement
obtain
cbc
corrected
nucleated
outweigh
rechallenge
genotoxicity
developmental
animal
deferiprone
organogenesis
13.1
0.62
0.16
deficiency
shire
onepath
phone
#
0660
icatibant
223
firazyr
n=75
n=38
sc
hae
trialsevents
firazyr(n
placebo(n
classpreferred
comprised
eligible
1,076
987
airway
facility
696
fulyzaq
229
139
146
crofelemer
bid*n
229n
placebon
274n
3.1
giardiasis
unconjugated
nephrolithiasis
pollakiuria
seasonal
salix
508
0024
www.salix.com
etiologies
presumptive
worsen
bradyarrhythmia
atrioventricular
blocks
multifocal
1212
gilenya
783
2-year
429
1716
4119
basal
n=783
n=773
tinea
versicolor
actinic
keratosis
benign
unspecified(including
cysts
polyps
papilloma
1-year
interferon
beta-1a
occlusive
conduction
pml
symptom
fundus
macula
pres
pft
childbearing
av
starts
recovers
postdose
diurnal
variation
pronounced
asymptomatic
magnitude
returns
697
24-hour
holter
n=351
n=346
mobitz
wenckebach
n=14
n=7
occasionally
atropine
isoproterenol
junctional
escape
6-hour
isolated
asystole
unexplained
20%-30
sequestration
lymphoid
suspending
reassess
reinitiation
fingolimod
infection(s
herpetic
relapses
meningitis
antineoplastic
modulating
switching
mode
unintended
professional
documentation
vzv
commencing
postponed
jc
jcv
disability
dna
csf
natalizumab
immunomodulatory
diverse
progress
clumsiness
limbs
orientation
personality
again
11/799
4/783
3/773
routine
ophthalmological
partially
residual
continuation
evolve
sequelae
diffusion
carbon
monoxide
dlco
insufficient
spirometric
3-fold
5-fold
dark
doubled
eliminate
persisting
pharmacodynamic
continuing
considerations
paronychia
boehringer
ingelheim
542
6257
459
9906
tty
orwww.fda.gov/medwatch
gilotrif
3800
2135
nsclc
naive
mutation
squamous
multicenter
documented
pemetrexed
cisplatin
11.0
thirds
asia
ild
14.0
left
ejection
fraction
lvef
institutional
dilation
n=1
mucosa
gilotrifn=229
cisplatinn=111
3*(%
cheilitis
soc
decreasedsoc
4(%
diarrheal
2.3,5.1
blistering
exfoliating
0.15
2.3,5.2
2.3,5.3
0.18
2.3,5.4
2.3,5.5
n=229
lasting
resolves
loperamide
loose
movements
cease
characterized
3865
asians
10.1
17.5
light
afatinib
embryotoxic
abortions
late
gestational
stages
kg
8.1and8.6
splenic
rupture
sickle
stimulatory
granix
numerically
teva
832
8537
myeloablative
n=348
n=240
n=92
filgrastim
subcutaneously
nadir
100,000
myeloid
attributable
granulocyte
colony
sweet
neutrophilic
dermatosis
determined
ards
angioneurotic
pruritic
shoulder
enlarged
spleen
infiltrates
antihistamines
bronchodilators
epinephrine
pegfilgrastim
crises
hemoconcentration
intensive
found
myelodysplasia
rls
phn
xenoport
877-xenoprt
936
6778
2,300
horizant
3,600
restless
1,201
613
371
2,400
515
600-mg
eleven
163
245
1,200
245)%
horizant600
163)%
horizant1,200
269)%
drunk
nutritional
libido
1,200-mg
postherpetic
neuralgia
417
207
principal
107
95)%
day(n
107)%
horizant2,400
82)%
horizant3,600
87)%
gabapentin
gynecomastia
kinase
warn
gained
operate
prodrug
14.3
impairs
own
competence
imperfect
car
tasks
differing
profiles
enacarbil
placebopatients
withevents
per1,000
patientswith
eventsin
drugpatients
incidencein
1,000patients
discontinuing
tapering
tumorigenic
carcinogenicity
acinar
adenoma
comprising
2,085
situ
knowledge
impossible
cohort
affected
inlyta
715
537
359
inc
22.0
5.0
20.1
199/359
220/355
34/359
46/355
n=359
n=355
polycythemia
320
316
317
309
312
310
315
336
318
314
291
319
338
331
313
311
hypernatremia
337
333
hypercalcemia
5.2,5.3
metastasis
temporarily
2.2,5.12
5.13,8.1
145/359
103/355
56/359
39/355
2/359
1/359
4/359
4/355
cerebrovascular
accident
artery
17/715
11/359
2/355
9/359
22/715
58/359
64/355
5/359
melena
11/355
3/355
6/359
1/355
5/715
4/715
69/359
29/355
hyperthyroidism
muu
79/245
25/232
euthyroid
formal
blindness
reinitiating
39/359
26/355
6/355
arms
axitinib
2.2),use
andclinical
mice
teratogenic
fetotoxic
seeuse
janssen
lp
800-janssen
526
7736
1203
tmc125-c206
tmc125-c216
hiv-1-infected
599
intelence
52.3
51.0
discontinuations
adrs
adr
9/60
15.0
51/539
3/60
10/539
nnrti
-related
excess
reactionsincludes
likely
intensityintensities
enough
incapacitating
intelence(r
term,%
brn=599
brn=604
br
gastroesophageal
reflux
hematemesis
retching
sluggishness
hemolytic
steatosis
reconstitution
dyslipidemia
paraesthesia
dreams
nightmares
night
sweats
lipohypertrophy
prurigo
acquired
lipodystrophy
haemorrhagic
parameterpreferred
daids
5*uln
1,500
1,999
1,499
750
999
749
50,000
99,999
49,999
6.20
7.77
l240
4.13
4.9
l160
190
5.65
8.48
l500
-750
8.49
13.56
l751
6.95
13.88
l161
13.89
27.75
l251
amino
infected
1129
permitted
27.8
25.0
6.7
tmc125-c213
101
hiv-1
weighing
13/64
20.3
2/37
4/64
0/37
limiting
rhabdomyolysis
constitutional
rashes
accompanied
aches
redistribution
accumulation
dorsocervical
buffalo
hump
wasting
cushingoid
responds
indolent
mycobacterium
avium
cytomegalovirus
pcp
necessitate
graves
polymyositis
secretagogues
mycotic
invokana
urination
pool
26-week
add
1667
n=833
n=834
n=646
fifty
hba1c
8.0
microvascular
mildly
patientsthe
metformin
sulfonylurea
pioglitazone
placebon=646
mgn=833
mgn=834
11.4
4.6
3.7
vulvovaginal
thirst
canagliflozin
larger
6177
1832
n=3092
n=3085
n=3262
energy
diffuse
polymorphic
sunburn
depletion
osmotic
diuresis
orthostatic
largest
loop
diuretics
group%
mg%
diuretic
8.8
falls
0.84
0.82
87.0
88.3
88.8
0.01
0.05
-1.6
-3.8
-5.0
-2.3
-3.4
placebon=90
mgn=90
mgn=89
1.61
1.62
1.63
40.1
39.7
38.5
0.28
-0.7
-4.6
-6.2
0.07
-1.5
-3.6
-4.0
4.1
carried
6.9
22.5
n=1085
dedicated
incident
8.9
9.3
vulvovaginitis
microbial
candidal
balanitis
balanoposthitis
uncircumcised
phimosis
circumcision
biochemical
assistance
recover
lost
obtained
sulfonylureas
hypoglycemianumber
biochemically
hypoglycemic
intent
monotherapy(26
placebo(n=192
mg(n=195
mg(n=197
metformin(26
metformin(n=183
metformin(n=368
metformin(n=367
metformin(52
glimepiride
metformin(n=482
metformin(n=483
metformin(n=485
165
sulfonylurea(18
sulfonylurea(n=69
sulfonylurea(n=74
sulfonylurea(n=72
12.5
sulfonylurea(26
sulfonylurea(n=156
sulfonylurea(n=157
15.4
27.4
30.1
sulfonylurea(52
sitagliptin
sulfonylurea(n=378
sulfonylurea(n=377
154
40.7
43.2
pioglitazone(26
pioglitazone(n=115
pioglitazone(n=113
pioglitazone(n=114
insulin(18
placebo(n=565
mg(n=566
mg(n=587
208
36.8
279
49.3
285
48.6
fractures
adjudicated
standing
height
extremities
n=723
sparing
remained
-0.6
9.2
14.8
4.4
8.2
104
-0.18
-1.1
0.47
0.51
absorptiometry
714
declines
hip
lumbar
spine
femoral
distal
forearm
correct
hypovolemia
elderly
acei
arb
predisposed
secretagogue
contraction
aldosterone
arbs
characteristics
macrovascular
conclusive
antidiabetic
marrow
sanofi
aventis
633
1610
jevtana
mitoxantrone
n=4
dysguesia
reactionsgraded
dailyn=371
4n
303
215
361
355
343
157
176
173
127
136
dysuria
septic
balanced
precise
mm3
2.2)(4
2.1)(5.2
formulated
polysorbate
premedication
cabazitaxel
dl.
premedicate
h2
rehydrate
emetics
diarrheals
identify
aggressively
ports
comorbidities
so
facilities
antiemetic
rehydration
emetic
nsaids
coagulants
radiotherapy
adhesions
uropathy
131
240
extensively
tolerability
abortifacient
ingrown
toenails
vesicles
valeant
north
america
321
4576
1227
jublia
1161
780
vehicle
jublian
vehiclen
413
toenail
kalydeco
cf
g551d
cftr
gene
nasal
congestion
vertex
634
8789
353
homozygous
f508del
8-week
crossover
design
g1244e
g1349d
g178r
g551s
g970r
s1251n
s1255p
s549n
s549r
r117h
132
prematurely
investigators
sputum
48-week
213
kalydecon=109n
placebon=104n
pleuritic
ivacaftor
granules
14.7
5/34
annually
cyp3a
rifampin
st.
john
wort
diminish
opacities
thrombocytopenic
uremic
kyprolis
6.1.1
lenalidomide
dexamethasone
myeloma
krd
details
rd
27/392
27/389
neuropathies
nec
hlt
embolic
smq
narrow
scope
search
arm(n
392
389
138
pneumoniaa
necb
dyspneac
venousd
hypertensione
aes
emerged
hyperuricemia
deafness
delirium
describes
rd(n
122
6.1.2
598
escalating
regimens
30/598
cyclophosphamide
monotherapy20/27
220
238
hypertensiond
kyprolis(n
184
ttp
hus
uric
infiltrative
thromboprophylaxis
medicate
neuro
cardiomyopathy
overload
york
clearance
calculated
cockcroft
gault
equation
burden
hydrated
lowering
pah
exclude
cardiopulmonary
syndromes
inform
nadirs
28-day
formerly
termed
along
carfilzomib
tachypnea
twitching
rigors
genzyme
745
4447
alglucosidase
alfa
infantile
juvenile
pompe
antipyretics
patients(n=39)n
programs
livedo
reticularis
nodal
rhythm
rales
sweat
scale
switched
4000
437
466
switch
youngest
n=60
n=30
wolff
parkinson
counseled
alfan=60n
placebon=30n
8.3
fluids
radioimmunoprecipitation
rip
igg
retrospectively
inhibitory
inhibition
furthermore
crim
infants
neutralize
seroconversion
evaluable
tended
1.2-
1.8-fold
undergone
ige
mast
warningandwarnings
rechallenged
slower
supervision
hypertrophic
warningandwarning
flu
stridor
apnea
hyperparathyroidism
mediated
membranous
glomerulonephritis
necrotizing
prepared
anesthesia
placement
intended
accompanying
extreme
biopsy
deposition
rhgaa
erythrocyte
sedimentation
persistently
improved
urinalysis
individualized
hypertrophy
complicated
defibrillation
ventilator
dependence
lose
mediators
marketed
service
box
concerns
depleting
dronedarone
af
afl
athena
euridis
adonis
erato
dafne
6285
3282
multaq
2875
premature
11.8
n=2875
n=3282
dyspeptic
asthenic
necessarily
n=2237
n=2701
demographic
flutter
1:1
leukocytoclastic
decompensated
decompensation
nyha
doubles
cardioverted
cardiovert
antithrombotic
teratogen
largely
arrhythmic
offers
consult
gain
worsens
hepatocellular
transplant
quadrant
investigate
explanation
induces
bazett
azotemia
tubular
secretion
reaches
plateau
hysterectomy
oophorectomy
counsel
contraceptive
choices
piramal
5245
neuraceq
978
administrations
872
positives
distortion
plaques
northera
supine
hyperpyrexia
lundbeck
455
1141
306
304
485
pure
autonomic
dopamine
hydroxylase
n=132
n=131
n=108
n=114
9.6
7.0
422
elevating
lessens
position
noh
elevate
sleeping
persists
neuroleptic
nms
japan
changed
levodopa
abruptly
neuroleptics
hyperthermia
rigidity
involuntary
fd&c
tartrazine
aspirin
nulojix
ptld
polyoma
nephropathy
graft
bristol
myers
squibb
721
5072
derive
de
novo
401
cyclosporine
405
403
basiliximab
induction
mycophenolate
mofetil
races
united
states
transplanted
lymphoproliferative
pooling
804
transplantation
145
476
identical
ebv
seropositive
seronegative
477
serostatus
nulojix-
9-fold
8/139
5/810
summary
n=477
n=472
n=476
n=43
n=28
n=404
n=48
n=20
n=399
n=57
cnsptld
11.6
subpopulation
cmv
4/210
1/596
404
recipients
serology
14/401
15/405
6/401
1096
recipient
mmf
causative
select
mucocutaneous
lived
n=401
n=405
designed
claims
1163
organism
specified
meeting
bk
299
329
327
infectionss
chagas
west
nile
dipstick
130/390
107/384
point
belatacept
molecule
372
cytotoxic
ctla-4
titer
dilution
reassessed
lives
region
bioassay
underreported
nodat
14/304
27/280
24/304
29/280
pressures
183
196
108
195
193
180
allograft
arteriovenous
stenosis
hydronephrosis
hematoma
immunity
epstein
barr
equipped
staffed
resources
responsible
requisite
susceptibility
uv
sunlight
rejection
minimization
utilization
capsid
vca
ebna
ascertained
ultraviolet
clothing
sunscreen
immunosuppressives
cerebrospinal
polymerase
chain
pcr
specialist
neurologist
pvan
mostly
functioning
tacrolimus
rejections
hla
mismatches
potentiation
depressants
dermatological
physical
psychological
onfi
drooling
lgs
volunteers
197
greatly
single-
allowing
n=179
n=58
n=62
categorized
distention
hypothermia
apathy
delusion
hallucination
reactions(including
necrolysis):discontinue
substance
abuse
habituation
depressant
cautioned
simultaneous
potentiated
tapered
precipitating
psychosis
hallucinations
discontinuance
benzodiazepines
extended
milder
dysphoria
introducing
psychotropic
predisposition
tension
celgene
423
5436
otezla
psa-1
psa-2
psa-3
1493
equally
tender
swollen
fashion
intable
2occurred
indicates
bid
5(n=495)n
112(n=490)n
5(n=497)n
112(n=493)n
tractinfection
movement
rash*1
1426
candidates
phototherapy
n=506)n
n=920)n
155
folliculitis
4/1184
weigh
phenobarbital
phenytoin
5.3,7.1
10/998
depressed
4/495
4/1441
0/495
3/1441
committed
12/920
2/506
1/1308
subjects(0/506
0/506
1/506
attempted
5%-10
49/497
16/495
96/784
19/382
16/784
3/382
apremilast
pradaxa
valvular
ly
anticoagulant
warfarin
5983
6059
5998
4936
4939
5193
2387
2405
2470
20.5
21.3
10,242
10,261
10,659
transfusion
packed
intracerebral
subarachnoid
subdural
bleeds
patientsa
apatients
subcategory
counted
contributed
subcategories
bannual
pt
whatever
365.25
cdefined
dintracranial
bleed
eon
itt
ffatal
investigator
gnon
mgn
6059n
/year
warfarinn
5998n
mgvs
warfarinhr
350
3.47
374
3.58
0.97
1.12
ich
0.22
0.77
0.29
0.46
0.37
0.17
0.38
0.67
162
1.59
1.05
1.51
1.19
1.92
0.45
0.19
1.10
0.08
0.35
0.09
1.28
0.59
2.02
subgroups
figure
exception
trend
comparisons
homogeneity
heterogeneity
interpreted
epigastric
gerd
esophagitis
erosive
4387
pivotal
cover
medy
sonate
55.1
87.7
10.3
105.6
classified
applied
intraspinal
compartment
retroperitoneal
intra
articular
1.24
parenteral
164
overlapped
randomization
mbe
belong
criterion
1430
rolled
473
684
0.66
0.32
0.34
24.7
22.7
spinal
epidural
eventspremature
anticoagulation
pathological
coverage
hematomaepidural
hematomas
neuraxial
paralysis
scheduling
indwelling
catheters
hemostasis
anticoagulants
traumatic
punctures
deformity
urgent
.consider
anticoagulated
urgently
bioprosthetic
valves
heparin
fibrinolytic
reversal
dabigatran
supporting
overdosage
activated
concentrates
apccs
feiba
recombinant
viia
protamine
k
antiplatelet
employed
analgesia
removal
best
exact
sufficiently
context
midline
deficits
cord
decompression
prosthetic
bileaflet
mechanical
align
implanted
enrollment
terminated
valve
hemodynamic
operatively
implantation
gp
serotonin
angle
closure
mania
hypomania
sexual
wyeth
pristiq
8,394
depressive
2,784
2,116
1,658
421
416
mdd
1,834
1,116
n=636
n=317
n=424
n=307
jittery
hesitation
yawning
senses
mydriasis
-dose
placebo(n=239
mg(n=108
mg(n=157
mg(n=131
mg(n=154
anorgasmia
orgasm
ejaculation
erectile
placebo(n=397
mg(n=209
mg(n=267
mg(n=176
mg(n=163
prolactin
stiffness
depersonalization
revascularization
lipoproteins
predetermined
cholesterol*(increase
261
fasting*(fasting
trace
final
hg
-1.4
bpm
-0.3
-0.4
-0.9
sdbp
revealed
suggestion
7/87
1/40
18/1,937
8/1,218
antidepressant
started
communication
ssris
snris
serotonergic
triptans
tricyclic
fentanyl
lithium
tramadol
tryptophan
buspirone
anatomically
angles
siadh
suicidality
strongest
predictors
inducing
phases
ocd
4,400
77,000
considerable
tendency
toward
stable
strata
fewer
extends
hostility
aggressiveness
impulsivity
nonpsychiatric
link
impulses
precursors
emerging
changing
worse
recognition
description
alerted
prescriptions
smallest
episode
presentation
believed
likelihood
precipitation
manic
conversion
screened
detailed
maois
linezolid
methylene
blue
labile
diaphoresis
myoclonus
incoordination
routes
maoi
nonsteroidal
reuptake
ecchymosis
petechiae
hemorrhages
pupillary
trigger
patent
iridectomy
affective
norepinephrine
selective
dysphoric
electric
sensations
emotional
lability
cessation
subsequently
antidiuretic
depleted
concentrating
unsteadiness
venlafaxine
parent
subtrochanteric
diaphyseal
prolia
adjuvant
aromatase
collect
www.proliasafety.com
ablation
3-year
multinational
7808
3876
3886
24.2
prolia(n
3886)n
3876)n
129
187
189
228
167
280
1347
34.7
1340
34.6
453
11.7
430
11.1
297
142
114
osteoarthritis
sciatica
178
149
4550
-5.5
-3.1
activator
kappa
ligand
rankl
expressed
lymph
nodes
abdomen
endocarditis
erysipelas
10.8
0.0001
21/2
erious
nonmetastatic
adt
1468
725
731
30.6
ai
252
10.5
11.5
9.9
6.0
parathyroid
pth
denosumab
monoclonal
electrochemiluminescent
bridging
8113
chemiluminescent
xgeva
thigh
groin
turnover
oversuppression
exacerbated
malabsorption
excision
intestine
d.
importance
spontaneously
extraction
preventive
dentistry
implants
angiogenesis
ill
fitting
dentures
surgeon
dentist
shaft
anywhere
just
lesser
trochanter
supracondylar
transverse
oblique
comminution
osteoporotic
resorptive
bilateral
prodromal
dull
aching
glucocorticoids
incomplete
femur
contralateral
7800
17.8
remodeling
evidenced
histomorphometry
promacta
itp
idiopathic
446
277
241
128
pattern
diseaseand
portal
thromboses
increaseda
955
peginterferon
ribavirin
aspirates
cytogenetic
chromosome
microangiopathy
ascites
antivirals
model
meld
score
establishment
inhibits
udp
glucuronosyltransferase
ugt)1a1
organic
anion
transporting
polypeptide
oatp)1b1
indirect
fractionation
stabilized
progressively
direct
reintroducing
reoccur
reinitiated
recur
31/955
5/484
v
leiden
atiii
antiphospholipid
normalize
elective
292
pvt
completing
/l.
underwent
eltrombopag
rodents
papules
900
6479
1,600
qutenza
394
scores
systempreferred
qutenza60
minutes(n
622)%
control60
495)%
dryness
hyperesthesia
excoriation
exfoliation
odor
near
mucous
membranes
airborne
capsaicin
coughing
vicinity
apply
cleansing
gel
wipe
off
gauze
shortly
membrane
scalp
aerosolization
patches
gently
rolling
adhesive
inward
cool
wiped
wash
soap
anesthetic
prepare
cooling
ice
analgesic
averaged
unrelated
unstable
sirturo
335
proposed
newly
mdr
noncomparative
9.4
25.6
19.8
groupn=79n
groupn=81n
unique
11/102
vs
6/105
22/230
9/79
2/81
value=0.03
18.2
discernible
16/233
ecgs
usage
120-week
window
prolongs
electrolytes
fluoroquinolones
antibacterial
antimycobacterial
clofazimine
torsade
pointes
bradyarrhythmias
uncompensated
bedaquiline
favorable
hepatotoxic
rifamycins
rifapentine
rifabutin
efavirenz
663
0412
stendra
2215
493
153
56.4
83.9
13.8
41.1
mg(n
217
712
request
536
stendra(n
711
3-month
minor
plausible
relation
imprecise
digestive
appendages
urogenital
erection
298
prostatectomy
12.1
435
58.2
intercourse
placebon=143
mgn=146
ophthalmologic
arteritic
naion
temporal
phosphodiesterase
pde5
anatomic
cup
disc
crowded
anatomical
5.4)andpatient
17.6
ed
options
inadvisable
alpha
antihypertensives
2.3,5.6,5.7
lasts
anticipated
5.4,6.2
hearing
outflow
aortic
subaortic
actions
vasodilators
suffered
90/50
170/100
vasodilatory
augment
sitting
adversely
principally
cyp450
isoform
avanafil
atazanavir
seedrug
erythromycin
amprenavir
aprepitant
diltiazem
fluconazole
fosamprenavir
verapamil
priapism
painful
erections
penile
deformation
penis
angulation
cavernosal
peyronie
literature
annual
observational
approximate
7.1)andclinical
classes
lightheadedness
fainting
demonstrate
optimized
stepwise
variables
act
compound
combinations
potentiates
aggregatory
nitric
sexually
transmitted
guard
immunodeficiency
lactic
tenofovir
df
stribild
gilead
sciences
800-gilead-5
1408
103
701
elvitegravir
cobicistat
emtricitabine
atripla
atv
rtv
truvada
reactionsfrequencies
stribildn=701
atriplan=352
truvadan=355
icterus
discussion
virologically
584
stably
boosted
pi
121
stayed
disoproxil
hyperpigmentation
palms
soles
n=701
n=352
amylase(>2.0
rbc
hpf
dexa
subset
-1.43
-3.68
-2.83
-3.77
earlier
144-week
lamivudine
stribild(n=701
atripla(n=352
truvada(n=355
0.14
/-0.14
/-0.12
/-0.15
-14.0
/-16.6
-1.9
/-17.9
-9.8
/-19.4
grades)(%
u
550
fasted
166[n=675
+17[n=535
161[n=343
+22[n=262
168[n=337
+16[n=243
43[n=675
+7[n=535
43[n=343
+9[n=262
42[n=335
+7[n=242
100[n=675
+15[n=535
97[n=343
+19[n=262
101[n=337
+18[n=242
122[n=675
+12[n=535
121[n=343
+5[n=262
132[n=337
+22[n=242
gt
osteomalacia
myopathy
fanconi
proximal
tubulopathy
insipidus
polyuria
headings
antiretrovirals
coinfected
virus-1
emtriva
viread
clcr
nephrotoxic
retroviral
complera
tybost
vitekta
hepsera
virologic
pathologic
suspended
alternatives
modest
excreted
combivir
epivir
epzicom
triumeq
trizivir
adefovir
dipivoxil
norvir
kaletra
steps
recommendations
review
beneficial
mineralization
arthralgias
jirovecii
